“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

In this video, Shyam Natarajan, PhD, discusses future research involving Unfold AI. He is an author of the recent BJUI Compass study, “Extracapsular extension risk assessment using an artificial ...

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while ...

No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort. Transperineal biopsy yielded a lower risk of infectious complications while ...

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

“Thriving in Urology” is a new video series hosted by urologist Amy M. Pearlman, MD, of the Prime Institute in Coral Gables, Florida.Each video will contain conversations on combating burnout by ...

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with ...

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS. Certain phenotypic and genomic biomarkers were found to be prognostic for radiographic progression-free survival ...

Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.

According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...

"From a revenue, profit and loss perspective, actually, in many instances, they anticipate that physicians may actually make more money using the second-generation CVAC device compared to traditional ...

“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," ...